16 April 2020 - Deborah Wilkes
Archived
Johnson & Johnson’s (J&J’s) OTC sales in the US increased by more than a third in the first quarter of 2020 amid the COVID-19 pandemic. Chairman and chief executive officer Alex Gorsky said the company had increased and refocused production of Tylenol (acetaminophen).
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.